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Neuralgic amyotrophy following botulinum toxin injectionqBotulinum toxin (BT) is a polypeptidic neurotoxin produced by
Clostridium botulinum that is widely used in medicine [1]. The U.S.
Food and Drug Administration (FDA) approved BT type A injection
use for the treatment of cervical dystonia, blepharospasm, primary
axillary hyperhydrosis and cosmetic use for glabellar lines, and it is
also widely used to treat spasticity, siallorhea, chronic tension-type
headache, and other diseases in ophthalmology, urology, gastroen-
terology, dermatology and orthopedics [1].
BT type A injections have a favourable safety and tolerability
proﬁle. Most reported adverse effects are benign and reversible,
including injection site reactions [2], focal weakness [2] such as
dysphagia, ptosis and strabismus, and subclinical effects on neuro-
muscular junctions of distant non-injected muscles [3]. Rare but
potentially dangerous complications have also been described,
including systemic botulism [4] and anaphylactic reactions [5],
and cases of distant nerve injury have also been reported.
A65year-old right-handedwomanwas referred forBT injection for
cervical dystonia of three years duration. BT type A (Botox A) was
injected to the left sternocleidomastoid and the right splenius capitis
muscle (total dose of 150units).While thepatient noted improvement
in neck stiffness and positioning, on the 8th day following injection,
she developed excruciating left arm pain radiating from the shoulder
to theelbow.Thepainwas severeenough tosendher to theemergency
room, where she was treated with oxycodone. Later that month, as
the pain subsided, left armweakness developed, including weakness
of internal rotation and abduction of the arm. An MRI of the shoulder
demonstrated edema of the supraspinatus and infraspinatus muscles
consistent with denervation of the suprascapular nerve, without
evidence of entrapment of the suprascapular nerve (Fig. 1) [6]. Nerve
conduction studies of the left arm were normal except for mild
left ulnar neuropathy at the elbow. Electromyogram (EMG) of the left
arm showed evidence of complete left suprascapular neuropathy
with ﬁbrillations and positive sharp waves, and no recruitable motor
units seen in the supraspinatus or the infraspinatus. There were 1þ
ﬁbrillations and positive sharp waves in the pronator teres and ﬂexor
carpi radialis, which may be consistent with C6–7 radiculopathy. The
rest of the EMG of the left arm, including the deltoid, biceps, triceps,
extensordigitorumlongus,ﬂexorcarpiulnarisandﬁrstdorsal inteross-
eous muscles, was normal. Over the course of the following four
months her pain resolved and she regainedmuscle strength; however,
cervical dystonia symptoms persisted. Re-treating her with BT injec-
tionwas deemed ill-advised.
Our patient’s acute clinical presentation is consistent with
Neuralgic Amyotrophy (NA) involving the upper trunk of the brachialq
The review of this paper was entirely handled by the Co-Editor-in-Chief,
Professor R.F. Pfeiffer.
1353-8020/$ – see front matter  2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.parkreldis.2009.09.007plexus. This pattern is the most commonly seen in idiopathic cases of
NA [7]. While rare, this is not the ﬁrst case of NA following BT treat-
ment. Five other cases have beenpreviously reported and are summa-
rized in Table 1 [8–11]. In these cases, NA usually developed after the
ﬁrst exposure to BTwith an average latency of 7 3 days. Themuscles
and nerves involved were distant from the injection site and, in some
cases, contralateralorevenbilateral. Follow-upperiodswereshort, and
complete recovery was documented in only one patient after 7
months. Pain remitted in all cases where it was present.
NA, also known as acute brachial plexitis or Parsonage-Turner
syndrome, is a rare entity affecting 2–4/100.000 persons per year
[12]. Epidemiological studies [7] support an inﬂammatory, immune-
mediated pathogenesis, as half the cases are associated with ante-
cedent viral infections, immunization or intravenous drug exposure
(streptokinase, heroin, interleukin-2, interferon-a2). Further support-
ing immune pathogenesis is the presence of anti-ganglioside anti-
bodies in some patients, [13] and peripheral lymphocytes sensitized
tobrachialplexusantigens [14].Recurrence isnotuncommon,affecting
up to 26% of patients [7]. Outcomemaybeunfavorable in two-thirds of
patients, with persistent pain or paresis at 3 years of follow-up [7].Fig. 1. Sagital proton density with fat suppression MRI of the left shoulder demon-
strating hyperintense signals in the supraspinatus (black arrow) and infraspinatus
(dotted arrow) consistent with acute denervation.
Table 1
Summary of previous reported cases of botulinum toxin-related neuralgic amyotrophy.
Case # Author,
year
Gender Age
(yrs)
Indication
for BT
BT type and
formulation
First
exposure
Total dose Temporal
relation
Relation to
injection site
Plexus
involvement
Outcome
1 Glanzman
et al. [11] 1990
F 53 Cervical
dystonia
A
Botox
Yes 120 U 2 days Ipsilateral Upper trunk Incomplete recovery
at 5 months
2 Sampaio
et al. [8] 1993
F 32 Cervical
dystonia
A
Dysport
Yes 1st tx: 800 U
2nd tx
(þ2 wks):
400 U
Pain 1 wk after
1st tx. Weakness
2 wks after 1st tx
Bilateral Upper trunk Not reported
3 Sheean
et al. [9] 1995
F 36 Writer’s
cramp
A
Dysport
Yes 1st tx: 40 U
2nd tx
(þ7 wks):
80 U
Pain 1 wk after
1st tx. Weakness
9 wks after
1st tx. 2 wks after
2nd tx
Ipsilateral Lower trunk Incomplete recovery
at 3 months.
4 Sheean
et al. [9] 1995
F 55 Writer’s
cramp þ
laryngeal
dystonia
A
Dysport
No 7th tx: 100 U
8th tx
(þ10 wks):
200 U
Pain 1 wk after
7th tx. Weakness
10 wks after
7th tx. 1 wk after
8th tx
Ipsilateral Upper trunk,
lower trunk,
post cord
Prolonged pain
(5–6 wks),
recovery not
reported
5 Tarsy [10]1997 M 55 Cervical
dystonia
A
Botox
Yes 160 U 10 days Contralateral Upper trunk Complete recovery in
7 months.
Re-administration of
BT without recurrence.
6 Present case F 65 Cervical
dystonia
A
Botox
Yes 150 U 8 days Ipsilateral Upper trunk Complete recovery in
4 months. No
re-administration of BT
BT – Botulinum toxin; wk – week.
Letter to the Editor / Parkinsonism and Related Disorders 16 (2010) 301–302302The temporal relationship between NA and BT injection suggests
a causal relationship. The injection siteswere distant from the affected
nerves and muscles, making direct injury of the nerves unlikely.
Cases of polyradiculopathy following botulinum toxin injections
have also been reported [15–17], supporting the hypothesis of
immune mediated peripheral nerve injury following BT injections.
Most reported cases to date were associated with arm or neck injec-
tions; this may suggest that the site of the injection plays a role in
the development of NA, or that the association between NA and BT
injections elsewhere on the body (e.g. face) were missed. Given the
suggested immune mediated nature of the reaction, it is possible
that similar complications can arise after injection for other medical
and cosmetic indications. The fact that cases have been reported
with two distinct preparations of botulinum toxin type A (Botox A
and Dysport) suggests that the antigen is the toxin itself and not
another protein in the product. Whether patients who developed
such a complication can be safely re-exposed to BT remains unknown,
and this should, in our opinion, probably not be tested [9,15].
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